|
 |
|
|||||||
|
|||||||||
DOI: 10.2337/db06-1419
© 2007 by the American Diabetes Association
CD8+ T-Cell Responses Identify ß-Cell Autoimmunity in Human Type 1 Diabetes
1 INSERM, U580, Paris, France
2 Université Paris Descartes, Faculté de Médecine René Descartes, Paris, France
3 INRA, Immuno-Endocrinology Unit, ENVN, Nantes, France; the Université de Nantes, Nantes, France
4 Università di Torino, Department of Internal Medicine, Torino, Italy
5 CHU de Nantes, Hôpital Hôtel-Dieu, Clinique d’Endocrinologie, Nantes, France
Address correspondence and reprint requests to Roberto Mallone or Peter van Endert, INSERM U580, Hôpital Necker, 161 rue de Sèvres, 75743 Paris Cedex 15, France. E-mail: mallone{at}necker.fr or vanendert{at}necker.fr
Abbreviations:
Ab, antibody; ELISpot, enzyme-linked immunospot; IFN, interferon; IGRP, islet glucose-6-phosphatase catalytic subunit–related protein; ISL8Spot, islet-specific CD8+ T-cell interferon-
enzyme-linked immunospot; PBMC, peripheral blood mononuclear cell; PPI, preproinsulin; SFC, spot-forming cells
Despite the understanding that type 1 diabetes pathogenesis is mediated by T-cells, detection of these rare lymphocytes remains largely elusive. Suitable T-cell assays are highly needed, since they could offer preclinical diagnoses and immune surrogate end points for clinical trials. Although CD4+ T-cell assays have met with limited success, CD8+ T-cells are increasingly recognized as key actors in the diabetes of the NOD mouse. CD8+ T-cells are likely to play a role also in humans and may provide new markers of ß-cell autoimmunity. Taking advantage of a panel of HLA-A2–restricted ß-cell epitopes derived from preproinsulin, GAD, and islet glucose-6-phosphatase catalytic subunit-related protein (IGRP), we have implemented an islet-specific CD8+ T-cell interferon- enzyme-linked immunospot (ISL8Spot) assay. The ISL8Spot assay is capable of detecting and quantifying ß-cell–reactive CD8+ T-cells directly ex vivo, without any preliminary expansion, using either fresh or frozen samples. Positive ISL8Spot responses separate new-onset diabetic and healthy samples with high accuracy (86% sensitivity, 91% specificity), using as few as five immunodominant epitopes. Moreover, sensitivity reaches 100% when the ISL8Spot assay is complemented by antibody determinations. Combination of CD8+ T-cell measurements with immune intervention strategies may open new avenues toward type 1 diabetes prediction and prevention.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  B. O. Roep Islet Autoreactive CD8 T-cells in Type 1 Diabetes: Licensed to Kill? Diabetes, May 1, 2008; 57(5): 1156 - 1156. [Full Text] [PDF]
|
|
|
|
|
|
E. Martinuzzi, G. Novelli, M. Scotto, P. Blancou, J.-M. Bach, L. Chaillous, G. Bruno, L. Chatenoud, P. van Endert, and R. Mallone The Frequency and Immunodominance of Islet-Specific CD8+ T-cell Responses Change after Type 1 Diabetes Diagnosis and Treatment Diabetes, May 1, 2008; 57(5): 1312 - 1320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Riboulet-Chavey, F. Diraison, L. K. Siew, F. S. Wong, and G. A. Rutter Inhibition of AMP-Activated Protein Kinase Protects Pancreatic {beta}-Cells From Cytokine-Mediated Apoptosis and CD8+ T-Cell-Induced Cytotoxicity Diabetes, February 1, 2008; 57(2): 415 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Jarchum, J. C. Baker, T. Yamada, T. Takaki, M. P. Marron, D. V. Serreze, and T. P. DiLorenzo In Vivo Cytotoxicity of Insulin-Specific CD8+ T-Cells in HLA-A*0201 Transgenic NOD Mice Diabetes, October 1, 2007; 56(10): 2551 - 2560. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |